Key result
Pharmacologic management of chronic stable angina in older adults lacks rigorous investigation, and drug selection should be based on patient comorbidities, adverse reaction profiles, and cost.
Why the study?
How should pharmacologic management of chronic stable angina be approached in older adults?
How should pharmacologic management of chronic stable angina be approached in older adults?
Highlights the lack of rigorous evidence for pharmacologic management of chronic stable angina in older adults and recommends individualized drug selection.
Insufficient evidence guides angina pharmacotherapy in older adults; leaves open comparative trials to define optimal agents.
Chronic stable angina is a significant problem in older adults. The goal of therapy is to provide symptomatic relief, improve patient quality of life, and prevent subsequent angina or myocardial infarction that could lead to sudden death. The efficacy and safety of drugs such as beta-blockers and calcium channel blockers for managing chronic stable angina in older adults has not been rigorously investigated. Drug selection should be based on physiologic alterations, patient comorbidities, adverse reaction profile, and cost.
No takes yet. Share an insight, caveat, or question.
Dixit et al. (2015) conducted a review in Chronic stable angina. Pharmacologic management (beta-blockers, calcium channel blockers) was evaluated. Pharmacologic management of chronic stable angina in older adults lacks rigorous investigation, and drug selection should be based on patient comorbidities, adverse reaction profiles, and cost.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: